Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · Real-Time Price · USD

4.605

+0.055 (1.21%)

At close: Feb 26, 2026, 4:00 PM EST

4.600

-0.005 (-0.11%)

After-hours: Feb 26, 2026, 4:10 PM EST

Relmada Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 26, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	338	16	125	105	625	521
Market Cap Growth	3531.20%	-87.41%	18.63%	-83.18%	19.93%	-6.06%
Enterprise Value	308	-38	18	-79	537	398
Last Close Price	4.55	0.52	4.14	3.49	22.53	32.07
PB Ratio	15.95	0.44	1.46	0.75	3.00	4.93
P/TBV Ratio	34.01	0.44	1.46	0.75	3.00	4.93
Net Debt / Equity Ratio	-1.47	-1.26	-1.13	-1.06	-1.02	-1.11
Net Debt / EBITDA Ratio	-	-	-	0.92	1.69	1.97
Net Debt / FCF Ratio	0.35	0.87	1.87	1.43	2.31	4.21
Quick Ratio	2.68	4.36	7.90	11.94	14.08	9.30
Current Ratio	2.86	4.45	8.00	12.26	14.83	9.37
Return on Equity (ROE)	-196.79%	-132.33%	-87.51%	-90.07%	-80.14%	-53.74%
Return on Assets (ROA)	-102.41%	-73.14%	-51.76%	-53.57%	-46.01%	-31.52%
Return on Capital Employed (ROCE)	-597.10%	-236.10%	-121.50%	-114.80%	-60.40%	-56.20%
Earnings Yield	-17.45%	-509.73%	-79.28%	-149.50%	-20.13%	-11.42%
FCF Yield	-12.42%	-329.85%	-41.46%	-98.81%	-14.71%	-5.34%
Buyback Yield / Dilution	-5.32%	-0.21%	-1.59%	-68.80%	-12.56%	-68.97%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q